## Evaluation of real-time PCR for HSV-VZV on various samples in the condition of a clinical virology laboratory

#### INTRODUCTION

Investigations for HSV-1, HSV-2 and VZV are justified by the frequency of these viral infections, their potential severity, and the availability of specific and effective anti-viral treatments.


Sensitive and fast real-time PCR techniques targeted to these viruses are now available. Our aim was to retrospectively evaluate a real-time PCR kit, HSV-1 HSV-2 VZV R-Gene on various samples in the usual conditions of a clinical virology laboratory.


#### **RESULTS**- continued


#### QUANTITATIVE data


The samples positive on Lightcycler equipment were evaluated by RotorGene. The correlation was good (0,95 for HSV1, 0,98 for HSV2, 0,99 for VZV).

# HSV1 Tous prélèvements confondus 10 9 7 \* 0,9779x - 0,6335 R\* = 0,3494 2 1 0 0 1 2 3 4 5 6 7 8 9 10 LightCycler 2.0 (Leg cy/mL)












Figure 2:
Comparison of quantitative data obtained by the real-time PCR kit on Lighcycler 2.0 (Roche) and RotorGene (Corbett) equipments

#### **METHODS**

106 samples of patients hospitalized in Strasbourg university hospital were studied by routine assays, cellular cultures or PCR, and the results later compared to those obtained by the real-time PCR kit (Argene)/ HSV-1 HSV-2 VZV R-Gene. 23 gynaecological swabs, 27 cutaneous and mucosal swabs, 8 samples from ear, nose, throat or eyes, 25 cerebrospinal (CSF) fluids, 23 broncho-alveolar or other samples were tested.

#### RESULTS

#### QUALITATIVE data

The data were globally concordant: for the 20 positive results of culture from gynaecological swabs, 9 HSV-1 and 9 HSV-2 were detected with the kit (*Argene*), while the 2 others were not confirmed, probably due to storage several months at –20°C. The 26 positive cutaneous and mucosal swabs were confirmed (11 HSV-1, 4 HSV-2, 11 VZV), as were the 6 positive from ear, nose, throat or eyes (6 HSV-1). For the CSF, 3 positive samples (*PCR consensus, Argene*) were confirmed (1 HSV-1, 2 VZV); an additional strain, i.e. VZV, was detected with the new kit in the 4th CSF. The other 21 negative CSFs were confirmed. For the broncho-alveolar and other liquids, 11 positive results were concordant (9 HSV-1, 2 VZV), 2 samples which were expected positive were not confirmed, and 10 negative samples were verified.

| Samples                                | POSITIVE<br>expected | NEGATIVE<br>expected |
|--|----------------------|----------------------|
| Gynaecological swabs                   | 18 / 20*             | 3/3                  |
| Cutaneous and mucosal swabs            | 26 / 26              | 1/1                  |
| Samples from ear, nose, throat or eyes | 6 sur 6              | 2/2                  |
| CSF                                    | 3/3                  | 21 / 22**            |
| LBA et autres liquides                 | 11 sur 13***         | 10 sur 10            |

### Figure 1:

\* the 2 discordant samples positive by cellular culture and stored several months at -20°C; \*\*1 positive by real-time PCR was not detected by "consensus" PCR; \*\*\*1 was weak positive, probably altered during conservation; the second was positive after re-testing

### Conclusion

The real-time PCR kit evaluated on various samples has given concordant qualitative results in 95% of the cases when compared to culture and conventional PCRs.

This technique will reduce the delay necessary to transmit results to physicians, and will add quantitative data for physicians.